In-Depth Insights into the Myelodysplastic Syndrome Market: Growth, Trends, and Opportunities for 2025-2034
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What Are the Projected Expansion Rates of the Myelodysplastic Syndrome Market for the Next Decade?
In recent years, the market size for myelodysplastic syndrome has experienced fast growth. An increase from $2.56 billion in 2024 to $2.85 billion in 2025 is projected, indicating a compound annual growth rate (CAGR) of 11.3%. The factors fueling this growth during the historical period include a rise in the incidence of myelodysplastic syndrome, heightened awareness about treatment options for the syndrome, an escalation in healthcare expenditure, and government programs.
The market size of myelodysplastic syndrome is anticipated to experience robust expansion in the coming years. Its projected growth is to reach $4.17 billion by 2029, with a compound annual growth rate (CAGR) of 10.0%. The expansion during the prediction period can be credited to factors such as the aging population, adoption of combination therapies, investments into hematologic investigation, and personalized medicine. The forecast period will also see a surge in innovative therapies for myelodysplastic syndrome, progress in diagnostic methods and techniques, clinical trials, and collaborative research.
What Industry-Specific Factors Are Fueling the Growth of the Myelodysplastic Syndrome Market?
The rising cases of rare malignancies linked to the blood is a key factor propelling the advancement of the myelodysplastic syndrome (MDS) market. These blood cancers represent a variety of hematologic malignancies that are not highly prevalent in the population. They emerge from the bone marrow, lymph nodes, and various elements of the blood and immune system cells. The primary goal in the treatment of myelodysplastic syndrome (MDS) is to control the disease by enhancing the creation of blood cells and managing the associated symptoms to hinder the advancement of blood cancer in the bone marrow. As per the data collected by the Leukemia and Lymphoma Society, an American professional body, around September 2024, every three minutes someone in America is diagnosed with leukemia, lymphoma or myeloma. Projections for 2024 estimate that about 187,740 people will be impacted by these cancers, equivalent to 9.4% of the expected 2,001,140 new cancer cases in America. Consequently, this increasing occurrence of blood cancer is stimulating the expansion of the myelodysplastic syndrome (MDS) market. The next driver for the myelodysplastic syndrome market is the anticipated upsurge in the frequency of bone marrow transplants, which are expected to promote the market’s growth in the future. A bone marrow transplant is a clinical procedure that involves the replacement of deteriorated or diseased bone marrow with healthy stem cells for treating various disorders. The hallmark of MDS is a failure of the bone marrow, an issue caused by the preferential growth of somatically changed clonal hematopoietic stem cells. This condition can be potentially cured by bone marrow transplantation that swaps the defective stem cells with healthy ones. In June 2024, per the National Transplant Organization (ONT), an independent coordinating body based in Spain, the country added 23,686 donors to the Spanish Bone Marrow Donor Registry in 2023 – that’s an 8% increase compared to 2022. This led to a record 3,717 hematopoietic stem cell transplants, equivalent to 77.4 transplants per million of the population. Therefore, the growing frequency of bone marrow transplants is fostering the expansion of the myelodysplastic syndrome market.
Request Your Free Myelodysplastic Syndrome Market Report Sample Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12920&type=smp
Which Companies Are Redefining the Future of the Myelodysplastic Syndrome Market?
Major companies operating in the myelodysplastic syndrome market are Pfizer Inc., Johnson and Johnson Limited, AbbVie Inc., Bayer AG, Novartis AG, Merck & Co., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc., Takeda Pharmaceutical Company Limited, Medtronic PLC, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Ltd., Jazz Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Lupin Limited, BeiGene, Janssen Biotech, Accord Healthcare, Acceleron Pharma Inc.
What Trends Are Poised to Drive the Future Success of the Myelodysplastic Syndrome Market?
Leading firms in the myelodysplastic syndrome (MDS) market are driving their market position with fresh therapy developments. For instance, Bristol Myers Squibb, a pharmaceutical company based in the US, received FDA authorization in August 2023 for Reblozyl (luspatercept-aamt), marking it as a pioneering therapy for anemia in ESA-naïve adults with low to intermediate risk myelodysplastic syndromes (MDS) who could potentially require regular RBC transfusions. Reblozyl demonstrated superior efficacy in the Phase 3 COMMANDS trial, securing RBC transfusion independence and increasing hemoglobin over epoetin alfa, allowing earlier anemia treatment in an expanded patient group.
Pre-order Your Report for Quick and Easy Delivery!
https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-global-market-report
What Are the Major Categories and Their Growth Dynamics in the Myelodysplastic Syndrome Market?
The myelodysplastic syndrome market covered in this report is segmented –
1) By Type: Myelodysplastic Syndrome With Unilineage Dysplasia, Myelodysplastic Syndrome With Multilineage Dysplasia, Myelodysplastic Syndrome With Ring Sideroblasts, Other Types
2) By Drug: Azacitidine, Lenalidomide, Decitabine, Deferasirox
3) By Treatment: Supportive Therapy, Growth Factors, Chemotherapy, Stem Cell Transplant, Other Treatments
4) By Route Of Administration: Oral, Injectable, Other Routes Of Administrations
5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users
Subsegments:
1) By Myelodysplastic Syndrome With Unilineage Dysplasia: Type Of Dysplasia, Patient Demographics
2) By Myelodysplastic Syndrome With Multilineage Dysplasia: Severity Of Dysplasia, Patient Demographics
3) By Myelodysplastic Syndrome With Ring Sideroblasts: Percentage Of Ring Sideroblasts, Treatment Options
4) By Other Types: Specific Types, Treatment Options
What Are the Leading Regions in the Myelodysplastic Syndrome Market Expansion?
North America was the largest region in the myelodysplastic syndrome market in 2024. The regions covered in myelodysplastic syndrome (MDS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Are the Core Features That Define the Myelodysplastic Syndrome Market?
Myelodysplastic syndrome (MDS) is a group of disorders characterized by the malfunctioning or abnormal development of bone marrow cells, leading to ineffective blood cell production. Myelodysplastic syndrome treatment improves blood cell counts, alleviates symptoms and delays disease progression. Myelodysplastic syndrome (MDS) can progress to acute myeloid leukemia (AML), a more aggressive form of blood cancer.
Browse Through More Similar Reports By The Business Research Company:
Cancer Clinical Decision Tools Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/cancer-clinical-decision-tool-global-market-report
Cancer Monoclonal Antibodies Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/cancer-monoclonal-antibodie-global-market-report
Chronic Lymphocytic Leukemia Treatment Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
